DelveInsight Evaluates a Robust Cystic Fibrosis Pipeline as 75+ Influential Pharma Players to Set Foot in the Domain

03 Jan 2023
www.prnewswire.com
Phase 2Phase 1
Cystic fibrosis is quickly becoming the most prevalent genetic illness in every region of the world. According to the Cystic Fibrosis Patient Registry, more than 30,000 persons in the United States are currently afflicted with this ailment, and it is projected that approximately 70,000 people throughout the world are afflicted with this condition.  The introduction of potential drugs is on the new horizon, which is bolstering market growth. Several companies are involved in evaluating novel therapies in different stages of development.
LAS VEGAS, Jan. 3, 2023 /PRNewswire/ -- DelveInsight's
'
Cystic Fibrosis Pipeline Insight – 2022
' report provides comprehensive global coverage of available, marketed, and pipeline cystic fibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the cystic fibrosis pipeline domain.
Key Takeaways from the Cystic Fibrosis Pipeline Report
DelveInsight's cystic fibrosis pipeline report depicts a robust space with
75+ active players working to develop
80+ pipeline therapies for cystic fibrosis treatment.
Key cystic fibrosis companies such as
Eloxx Pharmaceuticals, Arrowhead Pharmaceuticals, SolAeroMed, Parion Sciences, Translate Bio, Inc., Path BioAnalytics, Aridis Pharmaceuticals, Novartis, Vertex Pharmaceuticals, AlgiPharma, Spyryx Biosciences, Inc., Verona Pharma, Ionis Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Ligand Pharmaceuticals, Boehringer Ingelheim, OrPro Therapeutics, Protalix Biotherapeutics, Laurent Pharmaceuticals, Arcturus Therapeutics, Enterprise Therapeutics, Affinia Therapeutics, Sound Pharmaceuticals, Spirovant, 4D Molecular Therapeutics, Santhera Pharmaceuticals, Armata Pharmaceuticals, AbbVie, Krystal Biotech, BiomX, Inc., Moderna Therapeutics, ReCode Therapeutics, Aeon Respire, Kither Biotech, Carbon Biosciences, SpliSense, Sionna Therapeutics, Lung Therapeutics, Tavanta Therapeutics, Branca Bunús Ltd, and others are evaluating new cystic fibrosis drugs to improve the treatment landscape.
Promising cystic fibrosis pipeline therapies in various stages of development include
ELX-02, NM002, ARO ENaC, S-1226, P-1037, MRT5005, Cavosonstat, AR-501, QBW276, VX-121, OligoG, PTI-808, JBT-101, GLPG1837, POL6014, CB-280, Galicaftor, SPX-101, RPL554, IONIS-ENaCRx, CHF 6333, Theradux, PRX 110, LAU-7b, LUNAR-CF, ETD001, 4D-710, AP-PA02,Deutivacaftor/tezacaftor/vanzacaftor, Brensocatib, ABBV-576, KB 407, BX004-A, VXc-522, SP-101, mRNA-based therapeutic program, AR-001, KIT-2014, LTI-05, TAVT-135, BrB102, and others.
In
December 2022,
Vertex Pharmaceuticals announced that the US Food and Drug Administration had cleared its
Investigational New Drug (IND) application for
VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex
plans to initiate a single ascending dose clinical trial for VX-522 in people with CF.
In December 2022,
First Wave BioPharma, Inc. announced that it has selected the initial clinical trial sites for its
planned Phase II clinical trial to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). Based on anticipated regulatory and clinical trial activities, First Wave BioPharma
expects to report topline data from the Phase 2 trial
by mid-2023.
In December 2022,
Sionna Therapeutics, announced the
clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for
SION-638, a novel small molecule designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The
first subject has been dosed in a
Phase I study to evaluate the safety and pharmacokinetics of SION-638 in healthy volunteers.
In
December 2022,
Armata Pharmaceuticals, Inc. announced that the last subject has completed the company's
Phase I/II 'SWARM-P.a.' clinical trial of its lead candidate,
AP-PA02, in cystic fibrosis (CF) subjects with chronic pulmonary Pseudomonas aeruginosa infection. In March 2020, Armata announced that it had been
awarded up to $5 million in a therapeutic development award from the CF Foundation to advance development of AP-PA02. In October 2021, the Foundation subsequently made
an equity investment of $3 million in Armata to further support this program.
In
November 2022,
Aridis Pharmaceuticals, Inc. announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase IIa clinical trial of
AR-501 in cystic fibrosis (CF) patients. The Company is on track to complete database lock, data analyses, and disclose
top-line data in the first quarter of 2023.
In
September 2022,
Eloxx Pharmaceuticals, Inc. announced topline results from the
Phase II clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation. The combination trial of ELX-02 with ivacaftor was
well tolerated
but did not achieve statistical significance for efficacy endpoints, including changes from baseline in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1).
Request a sample and discover the recent advances in cystic fibrosis drug treatment @
Cystic Fibrosis Pipeline Report
The cystic fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage cystic fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the cystic fibrosis clinical trial landscape.
Cystic fibrosis is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most common variation reported globally, but there are over 2000 others, not all of which cause the disease. Cystic fibrosis symptoms typically appear 6-8 months after birth, though this varies greatly from person to person. Cystic fibrosis symptoms vary with age and can affect different body parts. Two tests for cystic fibrosis diagnosis are newborn screening, a genetic test to look for a gene defect, and a blood test to look for pancreatic problems. A sweat test can be performed after initial testing to confirm the cystic fibrosis diagnosis. Currently available cystic fibrosis medications aim at symptom relief, complication prevention, and, more recently, protein rectifiers to correct underlying structural and functional abnormalities.
Find out more about drugs for cystic fibrosis @
New Cystic Fibrosis Drugs
A snapshot of the Cystic Fibrosis Pipeline Drugs mentioned in the report:
Learn more about the emerging cystic fibrosis pipeline therapies @
Cystic Fibrosis Clinical Trials
Cystic Fibrosis Therapeutics Assessment
The
cystic fibrosis pipeline report proffers an integral view of cystic fibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Cystic Fibrosis Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment
By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
Therapeutics Assessment
By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment
By Mechanism of Action: Cystic fibrosis transmembrane conductance regulator modulators, Dipeptidyl peptidase I inhibitors, Cystic fibrosis transmembrane conductance regulator modulators, Cell membrane permeability enhancers, Bacterial growth inhibitor, Gene transference, Immunomodulators; Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators, Cystic fibrosis transmembrane conductance regulator replacements; Gene transference, Epithelial sodium channel antagonists, Cystic fibrosis transmembrane conductance regulator stimulants, Cystic fibrosis transmembrane conductance regulator expression modulators; RNA interference
Key Cystic Fibrosis Companies: Eloxx Pharmaceuticals, Arrowhead Pharmaceuticals, SolAeroMed, Parion Sciences, Translate Bio, Inc., Path BioAnalytics, Aridis Pharmaceuticals, Novartis, Vertex Pharmaceuticals, AlgiPharma, Spyryx Biosciences, Inc., Verona Pharma, Ionis Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Ligand Pharmaceuticals, Boehringer Ingelheim, OrPro Therapeutics, Protalix Biotherapeutics, Laurent Pharmaceuticals, Arcturus Therapeutics, Enterprise Therapeutics, Affinia Therapeutics, Sound Pharmaceuticals, Spirovant, 4D Molecular Therapeutics, Santhera Pharmaceuticals, Armata Pharmaceuticals, AbbVie, Krystal Biotech, BiomX, Inc., Moderna Therapeutics, ReCode Therapeutics, Aeon Respire, Kither Biotech, Carbon Biosciences, SpliSense, Sionna Therapeutics, Lung Therapeutics, Tavanta Therapeutics, Branca Bunús Ltd, and others.
Key Cystic Fibrosis Pipeline Therapies: ELX-02, NM002, ARO ENaC, S-1226, P-1037, MRT5005, Cavosonstat, AR-501, QBW276, VX-121, OligoG, PTI-808, JBT-101, GLPG1837, POL6014, CB-280, Galicaftor, SPX-101, RPL554, IONIS-ENaCRx, CHF 6333, Theradux, PRX 110, LAU-7b, LUNAR-CF, ETD001, 4D-710, AP-PA02,Deutivacaftor/tezacaftor/vanzacaftor, Brensocatib, ABBV-576, KB 407, BX004-A, VXc-522, SP-101, mRNA-based therapeutic program, AR-001, KIT-2014, LTI-05, TAVT-135, BrB102, and others.
Dive deep into rich insights for new drugs for cystic fibrosis treatment; visit @
Cystic Fibrosis Medications
Table of Contents
For further information on the cystic fibrosis pipeline therapeutics, reach out @
Cystic Fibrosis Drug Treatment
Related Reports
Cystic Fibrosis Epidemiology Forecast
Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the cystic fibrosis epidemiology trends.
Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key cystic fibrosis companies, including
Non-Cystic Fibrosis Bronchiectasis
Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-cystic fibrosis bronchiectasis companies, including
Non-Cystic Fibrosis Bronchiectasis Pipeline
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including
Non-Cystic Fibrosis Bronchiectasis Epidemiology
Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the non-cystic fibrosis bronchiectasis epidemiology trends.
Airway Clearance Devices for Cystic Fibrosis Market
Airway Clearance Devices for Cystic Fibrosis
Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key airway clearance devices for cystic fibrosis companies, including
Dymedso, PARI GmBH, Thayer Medical, Electromed, among others.
Other Trending Reports
Goitre Market
|
|
US Healthcare Outlook Report
|
|
Negative Pressure Wound Therapy Systems Market
|
Metrorrhagia Market
|
Dysfunctional Uterine Bleeding Market
|
|
Age-related Vision Dysfunction Market
|
Dental Lasers Market
|
CRISPR Therapies Pipeline Insight
|
Cell And Gene Therapy For Multiple Myeloma Market
|
Drug Hypersensitivity Market
|
Dysthymia Market
|
Persistent Depressive Disorder Market
|
Cancer Vaccines Market
|
Weight Loss/Weight Management (Cystic Fibrosis) Market
|
|
|
Tumor Ablation Market
|
Physiotherapy Equipment Market
|
CAR-T Pipeline Insight
|
Anti-hypertension Market
|
Radiofrequency Ablation Devices Market
|
Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
|
Gastro Intestinal Bleeding Market
|
Trastuzumab Biosimilars Insight
|
Varicose Veins Market
|
|
Intracardiac Echocardiography Devices Market
|
India Healthcare Outlook Report
|
Crows Feet Market Insight
|
|
Injectable Drug Delivery Devices Market
|
Structural Heart Devices Market
|
Substance (Drug) Abuse Market
Related Healthcare Blogs
Cystic Fibrosis: A Global Concern
Weight Loss and Cystic Fibrosis Market
Cystic Fibrosis Treatment Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.